Who gets to be a patient?
If psychedelic therapy becomes a real treatment, the next question is not whether it works but who will be able to reach it — and whether access will follow need or money.
Suppose the optimistic version comes true and one or more psychedelic therapies are approved for serious, hard-to-treat conditions. A quieter question immediately follows the celebratory one: who, in practice, will actually be able to receive them?
A labour-intensive treatment is an access problem
These are not pills you collect from a pharmacy. The model under study involves trained clinicians, hours of preparation, a supervised dosing session that can last most of a day, and integration over weeks. That is expensive and slow by design. Left to the market alone, a treatment with those properties tends to reach the affluent and well-connected first, and everyone else much later, if at all.
A therapy that only the comfortable can afford does not reduce suffering. It redistributes it upward.
The pattern is already visible
This is not hypothetical. Oregon's regulated psilocybin services, open since 2023, are paid for out of pocket, with a single supported session commonly costing well over a thousand dollars, because the programme sits outside medicine and no insurer covers it. Australia allowed authorised psychiatrists to prescribe psilocybin and MDMA from mid-2023, and the early reports were of a small number of providers charging fees in the tens of thousands of dollars. Esketamine, a nasal spray related to ketamine that was approved for depression in the United States in 2019, comes with clinic-supervised dosing and reached people with good insurance first.
The research population tells the same story from the other end. A 2018 review of psychedelic trials found that more than four in five participants were white, which means the evidence base is thinnest for many of the communities carrying the heaviest burden of untreated illness.
What designing for access looks like
- Training pathways that do not restrict this work to a small, costly elite.
- Coverage decisions that consider need, not only ability to pay.
- Research populations that resemble the people who will eventually need care, so the evidence actually generalises to them.
- Regulated routes that do not depend on living in the right state or province. Canada's Special Access Program, for instance, has allowed physicians to request psilocybin or MDMA for individual patients since 2022, but only case by case and only for those who find a willing prescriber.
The scientific question — does it work? — is being taken seriously. The distributive question — for whom? — deserves the same seriousness, and it has to be asked now, while the answers can still be shaped.
Sources and further reading
- Michaels TI et al. "Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature." BMC Psychiatry, 2018.
- Oregon Health Authority, Oregon Psilocybin Services.
- Therapeutic Goods Administration (Australia), change to classification of psilocybin and MDMA, effective 1 July 2023.
- Health Canada, Special Access Program: amendments to the Food and Drug Regulations, January 2022.
- US FDA approval of esketamine (Spravato) for treatment-resistant depression, March 2019.
This essay is general information, not medical advice. Access rules and costs change frequently; check current sources for your jurisdiction.